I

f you enjoyed the US edition of the CRISPR patent dispute, get ready for the European one: With the announcement last week that the European Patent Office intends to grant a patent to the University of California, Berkeley, and its partners covering a broad range of uses of the revolutionary genome-editing technology, expect a similar plot to unfold on that side of the Atlantic.

In particular, “now we go through opposition proceedings in Europe, where 3d parties can challenge the patent,” patent expert Jacob Sherkow of New York Law School tweeted. “And that could take a while.”

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Please help me i have server ulcer colitis crispr could be my cure to a normal life again please contact me @904 480 8891

  • Isn’t CRISPR-Cas9 gene editing set to be overtaken shortly by peptide nucleic acid (PNA) gene editing anyway making these legal fights somewhat pointless?

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.